Bioiberica Farma, the Spanish division of Bioiberica, has received approval for the combination of chondroitin and glucosamine in Spain. This is the first authorization of its kind in Europe.
Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
Bioiberica forms part of the consortium of companies working on the Senifood project, which carries out research on diets and foods of specific characteristics for the elderly with the aim of improving the nutrition of this age group.